At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
Reproxalap Ophthalmic Solution (0.25%) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
In Brief
A Phase 2 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), and 1 other intervention for Conjunctivitis, Allergic. Completed, enrolled 70 participants across 1 site.
Detailed Summary
An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctivitis, Allergic
CountriesCanada
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartOct 2018
First PostedOct 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedOct 17, 2018
Enrollment StartOct 2, 2018
Primary CompletionMar 20, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.7 years ago
Interventions
Reproxalap Ophthalmic Solution (0.25%)drug
Reproxalap Ophthalmic Solution (0.25%) dosed twice.
Reproxalap Ophthalmic Solution (0.5%)drug
Reproxalap Ophthalmic Solution (0.5%) dosed twice.
Vehicle Ophthalmic Solutiondrug
Vehicle Ophthalmic Solution dosed twice.